Ascendis Pharma A/S (ASND) vs Viatris (VTRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Viatris (VTRS) has outperformed Ascendis Pharma A/S (ASND) over the past year, gaining 74.9% versus a gain of 6.0%. Over five years, ASND leads with a +39.2% price change compared with +29.6% for VTRS. Viatris is the larger company by market cap ($20.03 billion vs $14.65 billion), about 1.4 times the size.
On valuation, Viatris trades at a lower forward P/E (6.5x vs 20.7x for Ascendis Pharma A/S). Viatris pays a dividend yielding 2.75%, while Ascendis Pharma A/S does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASND | VTRS |
|---|---|---|
| Share price | $222.69 | $17.44 |
| Market cap | $14.65B | $20.03B |
| 1-day change | -2.50% | -0.29% |
| YTD return | +4.43% | +40.08% |
| 1-year return | +5.98% | +74.92% |
| 5-year return | +39.19% | +29.57% |
| P/E ratio (TTM) | 17.06 | — |
| Forward P/E | 20.68 | 6.52 |
| EPS (TTM) | $13.05 | $-0.36 |
| Dividend yield | 0.00% | 2.75% |
| Annual dividend | $0.00 | $0.48 |
| Revenue (latest FY) | — | $14.30B |
| Revenue growth (YoY) | — | -2.98% |
| Net income (latest FY) | — | $-3.51B |
| Gross margin | — | 35.06% |
| Operating margin | — | -18.62% |
| Net margin | — | -24.58% |
| 52-week high | $282.15 | $18.43 |
| 52-week low | $186.05 | $9.69 |
| Distance from 52-week high | -21.07% | -5.37% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +37.34% | +12.96% |
| Average volume | 662.79K | 9.18M |
| Shares outstanding | 65.80M | 1.15B |
| Employees | 1,189 | 30,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VTRS has outperformed ASND by 68.9 percentage points over the past year.
- Viatris offers a meaningfully higher dividend yield (2.75% vs 0.00%).
About Ascendis Pharma A/S
ASND stock →Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,189 employees
About Viatris
VTRS stock →Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets.
Health Care · Biotechnology: Pharmaceutical Preparations · 30,000 employees
ASND vs VTRS FAQ
Which is bigger, Ascendis Pharma A/S or Viatris?
Viatris (VTRS) is larger, with a market capitalization of $20.03B compared with $14.65B for Ascendis Pharma A/S (ASND).
Which stock has performed better over the past year, ASND or VTRS?
VTRS returned +74.92% over the past 12 months, compared with +5.98% for ASND (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Ascendis Pharma A/S or Viatris?
Viatris pays a dividend yielding 2.75%, while Ascendis Pharma A/S does not currently pay a regular dividend.
Are Ascendis Pharma A/S and Viatris in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.